Ribosome Inactivating Proteins

This important reference provides up-to-date information on all aspects of ribosome-inactivating proteins (RIPs). Including a list of all known RIPs, their distribution in nature, structure, genetics and chemical and immunological properties, this reference covers mechanisms of action, including the enzymatic activity on various polynucleotide substrates; the interaction with, and entry into cells; the toxicity to animals, including the pathology of poisoning; and the immunomodulatory and allergenic activity. The book further emphasizes the use of immunotoxins and other conjugates in clinical trials for the therapy of cancer and intractable pain.

Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Ribosome Inactivating Proteins in a concise format. The editors have built Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Ribosome Inactivating Proteins in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Many plants produce enzymes collectively known as ribosome-inactivating proteins (RIPs). RIPs catalyze the removal of an adenine residue from a conserved loop in the large ribosomal RNA. The adenine residue removed by this depurination is crucial for the binding of elongation factors. Ribosomes modified in this way are no longer able to carry out protein synthesis. Most RIPs exist as single polypeptides (Type 1 RIPs) which are largely non-toxic to mammalian cells because they are unable to enter them and thus cannot reach their ribosomal substrate. In some instances, however, the RIP forms part of a heterodimer where its partner polypeptide is a lectin (Type 2 RIPs). These heterodimeric RIPs are able to bind to and enter mammalian cells. Their ability to reach and modify ribosomes in target cells means these proteins are some of the most potently cytotoxic poisons found in nature, and are widely assumed to play a protective role as part of the host plant’s defenses. RIPs are able to further damage target cells by inducing apoptosis. In addition, certain plants produce lectins lacking an RIP component but which are also cytotoxic. This book focuses on the structure/function and some potential applications of these toxic plant proteins.

Ribosome-inactivating proteins (RIPs) are rRNA N-glycosylases isolated mainly from plants that catalyze the hydrolysis of the N-glycosidic bond of a specific adenosine in the sarcin-ricin loop (SRL) of the major ribosomal RNA. Because the SRL is crucial for anchoring translation elongation factors, RIPs cause inactivation of ribosomes. They have been classified into two types based on the presence (type 2 RIPs) or absence (type 1 RIPs) of a lectin chain that can turn type 2 RIPs into potent toxins, such as ricin or abrin. The biological role of these proteins is unknown, but they are thought to be a defense mechanism of some plants against pathogens and predators. Because of their enzymatic action, RIPs show several biological activities, among which antiviral, antifungal and antiproliferative activities stand out. The most promising application of RIPs is their use as a component of immunotoxins, in which RIPs are linked to antibodies that mediate their binding and internalization by malignant cells. In agriculture, RIPs have been shown to increase resistance against viruses, fungi and insects in transgenic plants. The studies collected in this book provide the reader with an overview of the most current and interesting lines of research in the field of RIPs and their applications in medicine and agriculture. Thus, the reprint includes the isolation and biological properties of some new RIPs, both type 1 and type 2, the mechanisms of toxicity of previously described RIPs and two extensive reviews, one on the antiviral activity of RIPs and the other on the strategies used to improve their pharmacological properties.

Presenting all preclinical and clinical information available on genetically engineered toxins, this unique, single-source reference provides the most up-to-date methods and practical examples for conducting clinical studies in toxin molecular biology.;Reviewing difficult problems and their solutions, Genetically Engineered Toxins discusses techniques for clo;ning, expressing, and purifying recombinant toxins and genetically modified recombinant toxins; documents structure-function relationships in toxins, including comparative information; supplies theory and illustrations of chimeric toxins; delineates the preclinical assessments of new reagents; and summarizes approaches to drug design.;With over 1100 literature citations, Genetically Engineered Toxins is an invaluable resource for biochemists, molecular biologists, biotechnologists, pharmacologists, toxicologists, X-ray crystallographers, enzymologists, oncologists, hematologists, immunologists, rheumatologists, botanists, and graduate-level students in molecular biology, biotechnology, and clinical oncology courses.

This book is a printed edition of the Special Issue "Ribosome Inactivating Toxins" that was published in Toxins

Type 2 Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Type 2 Ribosome Inactivating Proteins in a concise format. The editors have built Type 2 Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Type 2 Ribosome Inactivating Proteins in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Type 2 Ribosome Inactivating Proteins: Advances in Research and Application: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.